Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

BACKGROUND: The bisdioxopiperazine dexrazoxane (DRZ) prevents anthracycline-induced heart failure, but its clinical use is limited by uncertain cardioprotective mechanism and by concerns of interference with cancer response to anthracyclines and of long-term safety. METHODS: We investigated the effe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Deng, Shiwei, Yan, Tiandong, Jendrny, Cathleen, Nemecek, Andrea, Vincetic, Mladen, Gödtel-Armbrust, Ute, Wojnowski, Leszek
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4242484/
https://ncbi.nlm.nih.gov/pubmed/25406834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-842
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia